Open access
Open access
Powered by Google Translator Translator

Oncology – Gynecologic

International consensus statements on pre-invasive vulvar lesions.

23 Jun, 2022 | 10:21h | UTC

The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) consensus statements on pre-invasive vulvar lesions – International Journal of Gynecological Cancer

News Release: New Guidelines Address Treatment of Pre-Invasive Lesions of the Vulva – Wolters Kluwer Health: Lippincott


ESMO Guideline: Diagnosis, treatment, and follow-up of endometrial cancer.

13 Jun, 2022 | 08:08h | UTC

Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up – Annals of Oncology


Screening every five years safe for women who test negative for HPV, study confirms.

9 Jun, 2022 | 11:26h | UTC

News Release: Screening every five years safe for women who test negative for HPV, study confirms – King’s College London

Original Study: Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data – The BMJ

Editorial: HPV screening for cervical cancer is reaching maturity – The BMJ

Related WHO Guidance:

News release: New recommendations for screening and treatment to prevent cervical cancer – World Health Organization

See guidance: WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention – World Health Organization

Related USPSTF Guidance: Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement – JAMA


#ASCO22 – RCT: Rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.

7 Jun, 2022 | 10:48h | UTC

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) – Journal of Clinical Oncology


A systematic review of the guidelines on venous thromboembolism prophylaxis in gynecologic oncology.

3 Jun, 2022 | 10:48h | UTC

A Systematic Review of the Guidelines on Venous Thromboembolism Prophylaxis in Gynecologic Oncology – Cancers


M-A: Association between benign ovarian tumors and ovarian cancer risk.

2 Jun, 2022 | 10:18h | UTC

Association Between Benign Ovarian Tumors and Ovarian Cancer Risk: A Meta-Analysis of Ten Epidemiological Studies – Frontiers in Oncology


Retrospective Cohort Study | Ovarian cancer detection in average-risk women: classic- versus nonclassic-appearing adnexal lesions.

30 May, 2022 | 10:58h | UTC

Ovarian Cancer Detection in Average-Risk Women: Classic- versus Nonclassic-appearing Adnexal Lesions at US – Radiology

News Release: Researchers use ultrasound to predict ovarian cancer – Radiological Society of North America

Commentary: Appearance of Ovarian Lesions on Ultrasound May Predict Malignancy – HealthDay


Commentary on Twitter


Position Paper: Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer.

26 May, 2022 | 10:42h | UTC

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies – ESMO Open


Phase 1/2 RCT: Safety and efficacy of the mTOR inhibitor, Vistusertib, combined With Anastrozole in patients with hormone receptor−positive recurrent or metastatic endometrial cancer.

26 May, 2022 | 10:30h | UTC

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)


Commentary on Twitter


Review: Outcomes of Enhanced Recovery after Surgery (ERAS) in gynecologic oncology.

6 May, 2022 | 10:22h | UTC

Outcomes of Enhanced Recovery after Surgery (ERAS) in Gynecologic Oncology: A Review – Current Oncology


Review: Advances in radiation oncology for the treatment of cervical cancer.

6 May, 2022 | 10:20h | UTC

Advances in Radiation Oncology for the Treatment of Cervical Cancer – Current Oncology


RCT: Topical imiquimod versus surgery for vulvar intraepithelial neoplasia.

3 May, 2022 | 10:30h | UTC

Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial – The Lancet (link to abstract – $ for full-text)


RCT: Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma.

20 Apr, 2022 | 09:09h | UTC

Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)


Advanced testing for human papillomavirus infection improves prognostic evaluation in cervical cancer.

18 Apr, 2022 | 09:33h | UTC

Human Papillomavirus Infection Determines Prognosis in Cervical Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)

Editorial: Testing for High-Risk Human Papillomavirus in Lower Genital Tract Tumors: If Knowledge Does Not Translate to an Action That Helps Patients—Why Do It? – Journal of Clinical Oncology

Commentary: Study Confirms Favorable Prognosis for HPV-Positive Cervical Cancer— RNA sequencing identified more HPV+ tumors, showed 43% mortality disparity for HPV- tumors – MedPage Today (free registration required)


RCT: Rucaparib vs. standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation.

6 Apr, 2022 | 09:45h | UTC

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: ARIEL4 Trial: Rucaparib vs Chemotherapy in Patients With Relapsed Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations – The ASCO Post


Commentary on Twitter


Cohort Study: Association of lower extremity lymphedema with physical functioning and activities of daily living among older survivors of colorectal, endometrial, and ovarian cancer.

28 Mar, 2022 | 08:39h | UTC

Association of Lower Extremity Lymphedema With Physical Functioning and Activities of Daily Living Among Older Survivors of Colorectal, Endometrial, and Ovarian Cancer – JAMA Network Open


Older female cancer survivors face challenges with physical activity due to chronic lower extremity lymphedema – News Medical

Lower-Extremity Lymphedema Common in Older, Female Cancer Survivors – HealthDay


Commentary on Twitter


SEOM-GEICO clinical guidelines on endometrial cancer.

25 Mar, 2022 | 08:24h | UTC

SEOM-GEICO clinical guidelines on endometrial cancer (2021) – Clinical and Translational Oncology


[News release – not published yet] RCT: Minimally invasive approach to hysterectomy in cervical cancer is associated with poorer disease-free survival than open surgery.

24 Mar, 2022 | 08:47h | UTC

Minimally Invasive Approach to Hysterectomy in Cervical Cancer Associated with Poorer Disease-Free Survival Than Open Surgery – Society of Gynecologic Oncology


M-A: Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy in BRCA1/2 pathogenic variant (PV) carriers.

22 Mar, 2022 | 07:58h | UTC

Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis – Journal of Clinical Oncology


Multi-disciplinary care planning of ovarian cancer in older patients.

18 Mar, 2022 | 07:55h | UTC

Multi-Disciplinary Care Planning of Ovarian Cancer in Older Patients: General Statement—A Position Paper from SOFOG-GINECO-FRANCOGYN-SFPO – Cancers


Trends in HPV–associated cancers, demographic characteristics, and vaccinations in the US, 2001-2017.

17 Mar, 2022 | 08:16h | UTC

Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017 – JAMA Network Open

Author Interview: Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations


[Not published yet] Single-dose HPV vaccine highly effective, researchers say – “Results of randomized controlled trial in Kenya bring new energy to eliminate cervical cancer worldwide”.

A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.

Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs


Systematic Review: Perioperative enhanced recovery programs for women with gynecological cancers.

16 Mar, 2022 | 10:05h | UTC

Perioperative enhanced recovery programmes for women with gynaecological cancers – Cochrane Library

See also: Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines (some guidelines are free)


RCT: In women undergoing cytoreductive surgery for ovarian cancer, the addition of hyperthermic intraperitoneal chemotherapy did not improve progression-free and overall survival.

16 Mar, 2022 | 09:41h | UTC

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial – JAMA Surgery


M-A: Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer.

RCT: Cytoreductive surgery for relapsed ovarian cancer.

Guide to enhanced recovery for cancer patients undergoing surgery: ERAS for Patients Undergoing Cytoreductive Surgery with or Without hyperthermic intraperitoneal chemotherapy.


Systematic Review: Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.

14 Mar, 2022 | 01:17h | UTC

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer – Cochrane Library


Management and care of patients with invasive cervical cancer: ASCO resource-stratified guideline rapid recommendation update.

14 Mar, 2022 | 00:40h | UTC

Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update – JCO Global Oncology

News Release: ASCO Guideline Recommends Addition of Monoclonal Antibody to Invasive Cervical Cancer Management – ASCO Daily News


Stay Updated in Your Specialty

No spam, just news.